Tokyo, Apr 25, 2005 (JCN) - Zoegene and Fujitsu (TSE: 6702) announced on April 21 that they have launched a joint project for developing innovative agents.
Under this partnership, the two companies will strive to discover hit compounds by leveraging their unique strengths: ZOEGENE's expertise in protein expression, crystal analysis and compound synthesis, and Fujitsu's proprietary drug discovery technology de novo SBDD.
Specifically, they aim to identify a compound that inhibits BACE-1, a beta-secretase enzyme that are considered to be a causing factor of Alzheimer's disease.
The two companies expect that this project will contribute to the development of innovative drugs for intractable diseases.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
 |
|
Fujitsu and Chulalongkorn University Launch Field Trials for Student Performance Management System to Enhance Student Support
(June 19, 2013)
|
|
|
Fujitsu Releases Interstage Terracotta BigMemory Max V4.0
(June 18, 2013)
|
|
|
Fujitsu Develops Thin Client Gateway Technology Enabling Use of PC Web Application Interfaces on Smart Devices
(June 18, 2013)
|
|
|
Fujitsu and MIT Announce Breakthrough Platform Technology for Improving Effectiveness of Online Learning
(June 17, 2013)
|
|
|
Fujitsu Develops Clock Distribution Circuit for High-Speed, Low-Power Data Transmission between CPUs
(June 14, 2013)
|
|
|
Fujitsu Launches New Models of Enterprise Desktop PCs and 1U Rack-mount Workstations
(June 12, 2013)
|
|
|
Fujitsu Develops New Technology to Enable Continued Use of IPv4 Services
(June 10, 2013)
|
|
|
Fujitsu to Begin Sample Shipments of the FM4 Family of 32-bit Microcontrollers in July with Initial Release of 84 Products
(June 7, 2013)
|
|
|
Fujitsu Launches New Lineup of FMV Series PCs with Four New Models
(June 5, 2013)
|
|
|
Fujitsu Launches docomo ARROWS NX F-06E Smartphone
(June 4, 2013)
|
|
|
